Anthem Biosciences Share Price

Conference Call with Anthem Biosciences Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 2 days 8 hours ago

Pharmaceuticals company Anthem Biosciences announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: In Q4FY26, the company reported consolidated revenue of Rs 6,109.43 million, marking an increase of 44.38% QoQ from Rs 4,231.53 million in Q3FY26 and a growth of 26.44% YoY compared to Rs 4,831.97 million in Q4FY25. For the full year ended March 31, 2026 (FY26), revenue stood at Rs 21,243.33 million, a 15.17% increase YoY from Rs 18,445.53 million in FY25. Total Income: Total income for Q4FY26 reached Rs 6,621.56 million, up 45.00% QoQ from Rs 4,566.83 million in Q3FY26 and up 33.16% YoY from Rs 4,972.59 million in Q4FY25. Annual total income for FY26 was Rs 22,801.16 million, representing an 18.12% growth over FY25's total income of Rs 19,302.85 million. Net Profit: Net profit for Q4FY26 stood at Rs 1,897.58 million, an increase of 104.44% QoQ from Rs 928.17 million in Q3FY26 and a 129.67% increase YoY from Rs 826.22 million in Q4FY25. Annual net profit for FY26 reached Rs 5,917.92 million, reflecting a growth of 31.14% YoY from Rs 4,512.60 million in FY25. Earnings Per Share (EPS): Basic EPS for Q4FY26 was Rs 3.38. For the full year FY26, basic EPS stood at Rs 10.55 compared to Rs 8.07 in FY25. Standalone Financial Highlights: Revenue from Operations: Standalone revenue for Q4FY26 was Rs 5,825.01 million, representing a 39.83% QoQ increase and a 21.61% YoY increase. Annual standalone revenue for FY26 reached Rs 20,893.12 million, an increase of 13.51% YoY from Rs 18,406.49 million in FY25. Total Income: Total income for Q4FY26 was Rs 6,431.26 million. For the full year FY26, standalone total income reached Rs 22,713.87 million, up 16.48% YoY. Net Profit: Net profit for Q4FY26 stood at Rs 2,116.65 million, up 88.78% QoQ and 72.70% YoY. Annual net profit for FY26 reached Rs 6,705.64 million, representing a growth of 32.47% YoY from Rs 5,061.88 million in FY25. Earnings Per Share (EPS): Basic EPS for FY26 was Rs 11.95 compared to Rs 9.05 in FY25. Business Highlights: Segment Performance (Consolidated): CRDMO: This segment recorded a revenue of Rs 17,727.68 million for FY26, representing a growth of 17.70% YoY from Rs 15,060.93 million in FY25. Gross profit for this segment stood at Rs 11,329.85 million for FY26. Speciality Ingredients: This segment recorded a revenue of Rs 3,515.65 million for FY26, a growth of 3.87% YoY from Rs 3,384.60 million in FY25. Gross profit for this segment was Rs 1,790.65 million for FY26. Final Dividend: The Board has recommended a final dividend of Rs 2.00 per equity share of face value of Rs 2.00 each for the financial year ended March 31, 2026. ESOP Allotment: The Board approved the allotment of 14,81,250 equity shares of face value Rs 2.00 each to eligible employees upon the exercise of options under the Anthem Employee Stock Option Plan 2024. Acquisition of Women’s Health Portfolio: The Board approved the acquisition of the Branded Generic Business relating to the Women's Health Portfolio of Bharat Serums and Vaccines Limited (BSV) through a slump sale for a consideration of Rs 797 crore. The transfer was effective November 01, 2025. Listing: The Company's equity shares were listed on NSE and BSE on July 21, 2025, following its IPO. Governance and Leadership: The Board approved the re-appointment of M/s. BPU & Co. as internal auditors for FY26-27 and recommended the continuation of Mr. Ravikant Uppal as Non-Executive Independent Director and the re-appointment of Mr. Ravindra Chandrappa as Whole Time Director. Ajay Bhardwaj, Chairman, MD and CEO, Anthem Biosciences, said: “We ended the financial year 2025–26 on a strong note, with our highest revenue quarter ever in Q4FY26. We delivered a Revenue growth of 26% YoY for the quarter and 15% YoY for the financial year 2025-26. Anthem’s commitment to prudent cost management and focus on long-term value creation has enabled us to expand profitability margins while delivering this revenue growth. Our EBITDA and PAT for the year grew by more than 30% in line with our growth aspirations. The Company continues to maintain a healthy financial position and remains committed to delivering sustainable growth across all business segments. As we step into financial year 2026–27, our priorities remain clear: to build one of the most agile, science-led, and future-ready CRDMO platforms in the world.” Result PDF

• Trendlyne
• 2 days 10 hours ago

Conference Call with Anthem Biosciences Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 3 months 2 weeks ago